Research Paper Volume 16, Issue 3 pp 2273—2298
Prognostic value and immune landscapes of anoikis-associated lncRNAs in lung adenocarcinoma
Figure 4. Evaluation of the ARlncRNA prognostic signature in the total, training and test cohorts. (A) Risk score distribution of patients with LUAD based on ARlncRNAs. (B) Scatter plots showed the association between the overall survival and the risk score distribution. (C) 1-, 3-, and 5-years overall survival area under the ROC curve of the signature. (D) Heatmap represented the expression of 11 ARlncRNAs involved in the signature.